Effect of Colesevelam HCl on Single-Dose Fenofibrate Pharmacokinetics
- 85 Downloads
The primary aim of this study was to determine whether there is an effect of colesevelam HCl (WelChol®; Sankyo Pharma Inc., Parsippany, NJ, USA) on fenofibric acid (active metabolite of fenofibrate, TriCor®, Abbott Laboratories, North Chicago, IL, USA) pharmacokinetics following single-dose fenofibrate when colesevelam HCl and fenofibrate are administered concomitantly, or when colesevelam HCl is administered 4 hours following fenofibrate therapy.
Thirty healthy volunteers were enrolled in a randomised, open-label, three-way crossover, drug interaction study. Subjects received one of three treatments at each of three dose administration periods: (i) treatment A -fenofibrate 160mg plus colesevelam HCl 3750mg (6 × 625mg tablets) administered with breakfast; (ii) treatment B - fenofibrate 160mg administered with breakfast, followed 4 hours later by colesevelam HC1 3750mg (6 × 625mg tablets) administered with lunch; or (iii) treatment C - fenofibrate 160mg administered with breakfast. Treatments were separated by a 10-day washout period. Blood samples were collected at predetermined time intervals, both before and after drug administration. Plasma concentrations of fenofibrate and fenofibric acid were measured using a validated liquid chromatography/mass spectroscopy/mass spectroscopy method.
Area under the concentration-time curve (AUC) from time zero to the timepoint of the lowest quantifiable concentration (AUCt), AUC from time zero to infinity (AUC∞) and maximum plasma concentration (Cmax) for fenofibric acid were 92.1%, 93.9% and 79.8%, respectively, of control values when colesevelam HC1 and fenofibrate were coadministered with breakfast; and 91.9%, 93.9% and 99.1%, respectively, when fenofibrate was administered followed 4 hours later by administration of colesevelam HC1. The 90% confidence intervals for the ratios of geometric means for AUCt, AUC∞ and Cmax comparing the three treatments were contained within the 80–125% equivalence range, with the exception of Cmax for treatment A. Coadministration of fenofibrate with colesevelam HCl resulted in an approximate 20% reduction in Cmax of the active metabolite (fenofibric acid). There were no significant differences in the time to Cmax, elimination rate constant or elimination half-life between any of the treatment groups.
Colesevelam HCl had no significant effect on fenofibrate bioavailability when administered either concomitantly with fenofibrate or 4 hours after fenofibrate.
KeywordsFenofibrate Ezetimibe Colestipol Colesevelam Bile Acid Sequestrant
This study was funded by Sankyo Pharma Inc. Drs Jones and Baker are employed by Sankyo Pharma Inc. Dr Mathew is employed by the Sankyo Clinical Pharmacology Unit, MDS Pharma Services.
- 1.NCEP-ATPIII. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): expert panel report. Bethesda (MD): National Heart, Lung, and Blood Institute; 2002 Sep. Report no.: NIH 02-5215Google Scholar
- 9.TriCor® fenofibrate tablets package insert. North Chicago (IL): Abbott Laboratories, 2001 AugGoogle Scholar
- 10.Colestid® package insert. Kalamazoo (MI): Pharmacia & Upjohn Company, 2003Google Scholar
- 11.LoCHOLEST powder package insert. Rockaway (NJ): Warner Chilcott Laboratories, 1998 MarGoogle Scholar
- 13.WelChol® (Colesevelam HC1) package insert v8. Parsippany (NJ): Sankyo Pharma Inc., 2003Google Scholar
- 16.Braunlin W, Zhorov E, Smisek D, et al. In vitro comparison of bile acid binding to colesevelam HC1 and other bile acid sequestrants. Polymer Preprints 2000; 41: 708–9Google Scholar
- 20.Metropolitan Life Insurance. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983; 64: 3–9Google Scholar
- 21.Rowland M, Tozer TN, editors. Clinical pharmacokinetics: concepts and applications. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1995Google Scholar
- 22.Data on file, Sankyo Pharma, Inc.Google Scholar
- 25.Zetia® (ezetimibe) package insert. North Wales (PA): Merck/Schering-Plough Pharmaceuticals, 2004Google Scholar
- 26.Lopid® package insert. Vega Baja; Pfizer Pharmaceuticals Ltd, 2003Google Scholar